EUVIMEDScopri EUVIMED
ÜbersichtsarbeitLeitlinieOpen access · CC BY 4.0

Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins

Yomnah Y Elsayed, Toni Kühl, Diana Imhof iD

Journal of Peptide Science · 2025-03 · 31 (3)

DOI: 10.1002/psc.70001 ↗

At a glance

Übersichtsarbeit in Journal of Peptide Science, published online on 2025-02-08. Written by Yomnah Y Elsayed and 2 co-authors. Institution: Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, Bonn, Germany. Major MEDLINE topics: Peptides, Proteins. Cited 51 times so far (Crossref); 169 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Peptides and proteins have become increasingly important in the treatment of various diseases, including infections, metabolic disorders, and cancers. Over the past decades, the number of approved peptide‐ and protein‐based drugs has grown significantly, now accounting for about 25% of the global pharmaceutical market. This increase has been recorded since the introduction of the first therapeutic peptide, insulin, in 1921. Therapeutic peptides and proteins offer several advantages over small molecule drugs, including high specificity, potency, and safety; however, they also face challenges related to instability in liquid formulations. To address this issue, numerous formulation techniques have been developed to enhance their stability. In either state, physical and chemical characterization of the peptide or protein of interest is crucial for ensuring the identity, purity, and activity of these therapeutic agents. Regulatory bodies such as the FDA, ICH, and EMA have established guidelines for the analysis, stability testing, and quality control of peptides and biologics to ensure the safety and effectiveness of these drugs. In the present review, these guidelines and the consequences thereof are summarized and provided to support the notion of developing tailored bioanalytical workflows for each peptide or protein drug.

Subjects

MeSH terms (MEDLINE)

PeptidesProteinsHumansGuidelines as TopicUnited States

Author keywords

bioanalyticsexcipientsformulationguidelinespeptidesproteins

Substances

PeptidesProteins

Authors and institutions

  • Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, Bonn, Germany.
  • Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.

ORCID profiles: Diana Imhof

Funding

  • Deutsche Forschungsgemeinschaft

Cite

APA

Elsayed, Y. Y., Kühl, T., & Imhof, D. (2025). Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins. Journal of Peptide Science, 31(3). https://doi.org/10.1002/psc.70001

Vancouver

Elsayed YY, Kühl T, Imhof D. Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins. Journal of Peptide Science. 2025;31(3). doi:10.1002/psc.70001

BibTeX
@article{Elsayed2025,
  author = {Elsayed, Yomnah Y and Kühl, Toni and Imhof, Diana},
  title = {Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins},
  journal = {Journal of Peptide Science},
  year = {2025},
  volume = {31},
  number = {3},
  doi = {10.1002/psc.70001}
}
Start for free →